Melanoma | Patterns of Care: Optimizing the Current Management of Melanoma with BRAF Mutation in the Real World

2:38:28
 
Share
 

Manage episode 282367918 series 1464173
By Dr Neil Love. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.

Featuring a roundtable discussion with Drs Adil Daud, Michael Postow, Hussein Tawbi and Jeffrey S Weber on the following topics:

  • Metastatic Disease
    • Introduction
    • Case: A woman in her early 50s with Stage IV melanoma and a solitary brain metastasis
    • Case: A man in his early 20s with metastatic melanoma with a BRAF mutation and CNS metastases
    • Case: A woman in her mid-80s with metastatic melanoma with a BRAF mutation who received encorafenib/binimetinib
    • Case: A man in his early 60s with widespread metastatic melanoma
    • Case: A man in his mid-80s with metastatic melanoma with a BRAF mutation and a PD-L1 CPS (combined positive score) of 10%
    • Available evidence and ongoing research with the combination of BRAF/MEK inhibitors and immunotherapy for advanced melanoma with a BRAF mutation
    • Assessment of PD-L1 level in deciding on first-line therapy for patients with metastatic melanoma
    • First-line therapy options for younger patients with metastatic melanoma with BRAF mutations
    • Case: A woman in her early 50s with melanoma with a BRAF mutation and brain metastases
    • Case: A man in his mid-70s with metastatic melanoma with a BRAF mutation
    • Similarities and differences among BRAF/MEK inhibitor combinations (dabrafenib/trametinib, vemurafenib/cobimetinib, encorafenib/binimetinib) used in the treatment of metastatic melanoma with a BRAF mutation
    • Effects of the COVID-19 pandemic on the clinical care of patients with melanoma
    • Case: A man in his mid-20s with newly diagnosed metastatic melanoma with a BRAF V600E mutation
    • Case: A woman in her late 40s with metastatic melanoma with a BRAF mutation
    • Thresholds for dose reduction and delay with dabrafenib/trametinib, vemurafenib/cobimetinib and encorafenib/binimetinib
  • Adjuvant Systemic Therapy
    • Case: A man in his early 70s with Stage IIIC melanoma and diabetes
    • Case: A woman in her early 50s with melanoma with a high tumor mutation burden
    • Case: A woman in her mid-60s with Stage IIIC melanoma with a BRAF V600E mutation
    • Use of encorafenib/binimetinib or vemurafenib/cobimetinib as adjuvant therapy
    • Potential contraindications for immune checkpoint inhibitors (eg, prior autoimmune disease, transplant)
    • Case: A woman in her early 50s with localized melanoma and a BRAF V600E mutation
    • Case: A woman in her early 70s with localized melanoma and a BRAF V600E mutation; duration of adjuvant therapy with BRAF/MEK combinations
    • Case: An otherwise healthy man in his early 30s with localized melanoma and a BRAF V600K mutation

CME information and select publications

2510 episodes